KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares RepurchasedShort-Term Debt issuances
Ratios

Abbott Laboratories (ABT) Long-Term Debt Repayments (2016 - 2025)

Historic Long-Term Debt Repayments for Abbott Laboratories (ABT) over the last 15 years, with Q3 2025 value amounting to $501.0 million.

  • Abbott Laboratories' Long-Term Debt Repayments rose 2495000.0% to $501.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 273.04%. This contributed to the annual value of $48.0 million for FY2021, which is 9639.91% down from last year.
  • According to the latest figures from Q3 2025, Abbott Laboratories' Long-Term Debt Repayments is $501.0 million, which was up 2495000.0% from $1.0 million recorded in Q2 2025.
  • Abbott Laboratories' Long-Term Debt Repayments' 5-year high stood at $1.4 billion during Q3 2023, with a 5-year trough of $1.0 million in Q2 2022.
  • Its 5-year average for Long-Term Debt Repayments is $269.4 million, with a median of $3.0 million in 2021.
  • As far as peak fluctuations go, Abbott Laboratories' Long-Term Debt Repayments surged by 14440000.0% in 2023, and later plummeted by 9986.16% in 2024.
  • Abbott Laboratories' Long-Term Debt Repayments (Quarter) stood at $3.0 million in 2021, then plummeted by 66.67% to $1.0 million in 2022, then soared by 144400.0% to $1.4 billion in 2023, then plummeted by 99.86% to $2.0 million in 2024, then skyrocketed by 24950.0% to $501.0 million in 2025.
  • Its Long-Term Debt Repayments was $501.0 million in Q3 2025, compared to $1.0 million in Q2 2025 and $1.0 billion in Q1 2025.